La psychopharmacologie des Mises à jour pour les Prescripteurs

A guide to management of treatment-resistant OCD, covering proper diagnostic criteria, evidence-based SSRI dosing protocols, systematic augmentation strategies, and advanced interventions such as TMS, DBS, and ablative surgery for refractory cases.

This guide provides a comprehensive review of trazodone, a serotonin antagonist and reuptake inhibitor (SARI) FDA-approved for depression but predominantly prescribed off-label for insomnia, covering its dose-dependent pharmacology, clinical uses, drug interactions, side effects including priapism and QT prolongation, and special population considerations.

A discussion on lithium dosing and side effect management in bipolar disorder, covering therapeutic levels, renal protection strategies, weight gain mechanisms, nephrogenic diabetes insipidus, cognitive effects, tremor differentiation, and dermatologic complications with practical solutions for clinical challenges.

What are the six key tips for switching oral antipsychotics? Does deprescribing antipsychotics after delirium improve outcomes in older adults? Why is xylazine overdose difficult to treat? What does the PAX-D study reveal about pramipexole for depression? Do bioequivalent medications always produce equivalent clinical results?

This guide provides a comprehensive overview of 2025's key regulatory and guideline updates in psychiatry, covering new FDA approvals, label changes, and practice guidelines across depression, schizophrenia, addiction, neurocognitive disorders, and neurodevelopmental conditions, emphasizing practical implementation considerations for clinicians.

A review of drug-induced movement disorders and cognitive side effects from psychotropic medications. The presentation covers diagnostic criteria, management strategies, and evidence-based treatments for akathisia, extrapyramidal symptoms, tardive dyskinesia, and medication-induced tremors.

How effective is the new antipsychotic KarXT using the number needed to treat metric? Can bright light therapy effectively treat bipolar depression without causing mania? Does IV haloperidol really increase cardiac risks as commonly believed? Can varenicline help reduce alcohol intake in people with alcohol use disorder? Does ashwagandha extract improve cognitive function in mild cognitive impairment?

This newsletter provides information about the FDA's recent approval of iloperidone to treat bipolar I disorder in adults. It discusses the drug's effectiveness, recommended dosages, and potential adverse effects. We also share key points from an interview on the principles of psychodynamic psychopharmacology, a presentation on the evidence supporting the application of TMS in the treatment of various psychiatric disorders and its potential side effects, and our practical research summaries of child, adolescent, and adult psychiatry.

In this volume, we explore topics such as the long-term management of OCD in youth and whether probiotics have a role in managing ADHD symptoms. Are probiotics combined with methylphenidate showing promise? We also shed light on the controversial use of electroconvulsive therapy (ECT) for adolescents battling severe depression and suicidality. What factors influence its effectiveness? Our exploration continues with noninvasive brain stimulation techniques for neurodevelopmental disorders. How do we ensure their safe application in this population? Lastly, we question the long-term efficacy of escitalopram in adolescents with major depressive disorder (MDD).

This interview discusses the use of lithium, thyroid hormone, second-generation antipsychotics, newer antidepressants, and ketamine/esketamine as adjunctive agents in managing major depressive disorder.